Please login to the form below

Not currently logged in


This page shows the latest elotuzumab news and features for those working in and with pharma, biotech and healthcare.

AbbVie's PARP inhibitor veliparib fails to deliver

AbbVie's PARP inhibitor veliparib fails to deliver

AbbVie will draw comfort from its stake in three fast-growing blood cancer drugs - Imbruvica (ibrutinib), Venclexta (venetoclax) and Empliciti (elotuzumab) - and several mid-stage candidates including antibody drug conjugates (ADCs)

Latest news

More from news
Approximately 6 fully matching, plus 21 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Healthcare Media Europe – HME

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....